BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND MLLT3, AF9, 4300, ENSG00000171843, P42568, YEATS3, AF-9 AND Treatment
144 results:

  • 1. Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-af9 leukemia.
    Li Y; Seet CS; Mack R; Joshi K; Runde AP; Hagen PA; Barton K; Breslin P; Kini A; Ji HL; Zhang J
    Stem Cell Reports; 2024 Jan; 19(1):100-111. PubMed ID: 38101400
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Transformation from acute promyelocytic leukemia in pregnancy to acute myeloid leukemia with MLL-af9 fusion gene: A case report and literature review.
    Gao Y; Han N; Jiang Y; Lu Z
    Medicine (Baltimore); 2023 Dec; 102(48):e36403. PubMed ID: 38050244
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Uncovering NOTCH1 as a Promising Target in the treatment of
    Fischer J; Erkner E; Fitzel R; Radszuweit P; Keppeler H; Korkmaz F; Roti G; Lengerke C; Schneidawind D; Schneidawind C
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833915
    [No Abstract]    [Full Text] [Related]  

  • 4. Droplet Digital PCR for Oncogenic KMT2A Fusion Detection.
    Young AL; Davis HC; Challen GA
    J Mol Diagn; 2023 Dec; 25(12):898-906. PubMed ID: 37813299
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Distinct and targetable role of calcium-sensing receptor in leukaemia.
    Pereira RS; Kumar R; Cais A; Paulini L; Kahler A; Bravo J; Minciacchi VR; Krack T; Kowarz E; Zanetti C; Godavarthy PS; Hoeller F; Llavona P; Stark T; Tascher G; Nowak D; Meduri E; Huntly BJP; Münch C; Pampaloni F; Marschalek R; Krause DS
    Nat Commun; 2023 Oct; 14(1):6242. PubMed ID: 37802982
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Interleukin-6 Facilitates Acute Myeloid leukemia Chemoresistance via Mitofusin 1-Mediated Mitochondrial Fusion.
    Hou D; Zheng X; Cai D; You R; Liu J; Wang X; Liao X; Tan M; Lin L; Wang J; Zhang S; Huang H
    Mol Cancer Res; 2023 Dec; 21(12):1366-1378. PubMed ID: 37698549
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
    Liu Y; Klein J; Bajpai R; Dong L; Tran Q; Kolekar P; Smith JL; Ries RE; Huang BJ; Wang YC; Alonzo TA; Tian L; Mulder HL; Shaw TI; Ma J; Walsh MP; Song G; Westover T; Autry RJ; Gout AM; Wheeler DA; Wan S; Wu G; Yang JJ; Evans WE; Loh M; Easton J; Zhang J; Klco JM; Meshinchi S; Brown PA; Pruett-Miller SM; Ma X
    Nat Commun; 2023 Apr; 14(1):1739. PubMed ID: 37019972
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation.
    Lu Y; Yang L; Shen M; Zhang Z; Wang S; Chen F; Chen N; Xu Y; Zeng H; Chen M; Chen S; Wang F; Hu M; Wang J
    Leukemia; 2023 May; 37(5):1039-1047. PubMed ID: 36997676
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
    Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
    BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.
    Casado P; Rio-Machin A; Miettinen JJ; Bewicke-Copley F; Rouault-Pierre K; Krizsan S; Parsons A; Rajeeve V; Miraki-Moud F; Taussig DC; Bödör C; Gribben J; Heckman C; Fitzgibbon J; Cutillas PR
    Signal Transduct Target Ther; 2023 Feb; 8(1):80. PubMed ID: 36843114
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Comprehensive molecular understanding of pediatric acute myeloid leukemia.
    Shiba N
    Int J Hematol; 2023 Feb; 117(2):173-181. PubMed ID: 36653696
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Lineage switch in a pediatric patient with KMT2A-mllt3 from acute megakaryoblastic leukemia to T cell acute lymphoblastic leukemia at the fourth relapse after allo-HSCT: with literature review.
    Gao L; Lu J; Li J; Hu Y; Lu Y; Du W; Hu S
    Int J Hematol; 2023 May; 117(5):781-785. PubMed ID: 36472792
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.
    Liu X; Sato N; Yabushita T; Li J; Jia Y; Tamura M; Asada S; Fujino T; Fukushima T; Yonezawa T; Tanaka Y; Fukuyama T; Tsuchiya A; Shikata S; Iwamura H; Kinouchi C; Komatsu K; Yamasaki S; Shibata T; Sasaki AT; Schibler J; Wunderlich M; O'Brien E; Mizukawa B; Mulloy JC; Sugiura Y; Takizawa H; Shibata T; Miyake K; Kitamura T; Goyama S
    EMBO Mol Med; 2023 Jan; 15(1):e15631. PubMed ID: 36453131
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Pharmacological targeting of type phosphodiesterase 4 inhibits the development of acute myeloid leukemia by impairing mitochondrial function through the Wnt/β-catenin pathway.
    Mao P; Huang C; Li Y; Zhao Y; Zhou S; Zhao Z; Mu Y; Wang L; Li F; Zhao AZ
    Biomed Pharmacother; 2023 Jan; 157():114027. PubMed ID: 36436494
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
    Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
    BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia.
    Karlsson L; Nyvold CG; Soboli A; Johansson P; Palmqvist L; Tierens A; Hasle H; Lausen B; Jónsson ÓG; Jürgensen GW; Ebbesen LH; Abrahamsson J; Fogelstrand L
    Int J Lab Hematol; 2022 Dec; 44(6):1094-1101. PubMed ID: 35918824
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. KDM4 inhibitor SD49-7 attenuates leukemia stem cell
    Li Y; Wang C; Gao H; Gu J; Zhang Y; Zhang Y; Xie M; Cheng X; Yang M; Zhang W; Li Y; He M; Xu H; Zhang H; Ji Q; Ma T; Ding S; Zhao Y; Gao Y
    Theranostics; 2022; 12(11):4922-4934. PubMed ID: 35836814
    [No Abstract]    [Full Text] [Related]  

  • 19. A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid leukemia Cells.
    Zhang K; Gao L; Wang J; Chu X; Zhang Z; Zhang Y; Fang F; Tao Y; Li X; Tian Y; Li Z; Sang X; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Pan J; Hu S
    Pathol Oncol Res; 2022; 28():1610447. PubMed ID: 35832114
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-af9/MLL-ENL.
    Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
    J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 8.